Design safer, more efficient therapeutics

Anti-drug antibodies (ADAs) can compromise drug efficacy and lead to immunogenicity-related adverse effects. Understanding ADA responses is critical for developing safe, effective biotherapeutics.

We provide high-resolution peptide microarray-based ADA epitope mapping, helping researchers identify immunogenic hotspots, pre-existing and drug-related antibody responses, and make date-driven decisions to optimize biotherapeutic design and treatment.